CA2120755A1 - Pharmaceutical compositions comprising a calcitonin, a glycyrrhizinate as absorption enhancer and benzyl - Google Patents

Pharmaceutical compositions comprising a calcitonin, a glycyrrhizinate as absorption enhancer and benzyl

Info

Publication number: CA2120755A1
Authority: CA; Canada
Prior art keywords: glycyrrhizinate; benzyl alcohol; calcitonin; composition; composition according
Prior art date: 1991-10-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002120755A

Other languages

English (en)

French (fr)

Inventor

Laura Chiodini

Teodoro Fonio

Mario Pinza

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GlaxoSmithKline SpA

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-10-11

Filing date

1992-10-08

Publication date

1993-04-15

1992-10-08 Application filed by Individual filed Critical Individual

1993-04-15 Publication of CA2120755A1 publication Critical patent/CA2120755A1/en

Status Abandoned legal-status Critical Current

Links

LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 title claims abstract description 94
102000055006 Calcitonin Human genes 0.000 title claims abstract description 28
108060001064 Calcitonin Proteins 0.000 title claims abstract description 28
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title claims abstract description 28
229940074774 glycyrrhizinate Drugs 0.000 title claims abstract description 27
229960004015 calcitonin Drugs 0.000 title claims abstract description 23
238000010521 absorption reaction Methods 0.000 title claims abstract description 20
239000003623 enhancer Substances 0.000 title claims abstract description 12
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 title description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract description 184
235000019445 benzyl alcohol Nutrition 0.000 claims abstract description 61
239000003937 drug carrier Substances 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 115
DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 claims description 39
108700032313 elcatonin Proteins 0.000 claims description 39
229960000756 elcatonin Drugs 0.000 claims description 39
239000007788 liquid Substances 0.000 claims description 12
125000005456 glyceride group Chemical group 0.000 claims description 8
239000007864 aqueous solution Substances 0.000 claims description 6
239000003755 preservative agent Substances 0.000 claims description 6
230000002335 preservative effect Effects 0.000 claims description 6
239000007921 spray Substances 0.000 claims description 6
210000004877 mucosa Anatomy 0.000 claims description 4
229960004217 benzyl alcohol Drugs 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 1
231100000252 nontoxic Toxicity 0.000 claims 1
230000003000 nontoxic effect Effects 0.000 claims 1
208000001132 Osteoporosis Diseases 0.000 abstract description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 86
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 84
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 46
238000009472 formulation Methods 0.000 description 37
229960004106 citric acid Drugs 0.000 description 29
235000015165 citric acid Nutrition 0.000 description 29
239000012153 distilled water Substances 0.000 description 29
238000002360 preparation method Methods 0.000 description 26
239000011780 sodium chloride Substances 0.000 description 23
239000000243 solution Substances 0.000 description 19
229960000999 sodium citrate dihydrate Drugs 0.000 description 18
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 18
238000002156 mixing Methods 0.000 description 16
230000001105 regulatory effect Effects 0.000 description 13
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 12
239000000499 gel Substances 0.000 description 12
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
239000011575 calcium Substances 0.000 description 11
229910052791 calcium Inorganic materials 0.000 description 11
238000000034 method Methods 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 11
210000002966 serum Anatomy 0.000 description 11
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
239000002202 Polyethylene glycol Substances 0.000 description 10
239000008101 lactose Substances 0.000 description 10
229920001223 polyethylene glycol Polymers 0.000 description 10
239000003826 tablet Substances 0.000 description 10
239000011734 sodium Substances 0.000 description 9
229910052708 sodium Inorganic materials 0.000 description 9
239000000829 suppository Substances 0.000 description 9
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
229930195725 Mannitol Natural products 0.000 description 8
239000007903 gelatin capsule Substances 0.000 description 8
239000000594 mannitol Substances 0.000 description 8
235000010355 mannitol Nutrition 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 7
239000002775 capsule Substances 0.000 description 7
239000000843 powder Substances 0.000 description 7
235000012431 wafers Nutrition 0.000 description 7
239000002552 dosage form Substances 0.000 description 6
VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical class C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000007787 solid Substances 0.000 description 6
LRZSAGKIMYFLHY-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;dihydrate Chemical compound O.O.OC(=O)CC(O)(C(O)=O)CC(O)=O LRZSAGKIMYFLHY-UHFFFAOYSA-N 0.000 description 5
239000000443 aerosol Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000012669 liquid formulation Substances 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
239000012528 membrane Substances 0.000 description 5
239000001509 sodium citrate Substances 0.000 description 5
239000004471 Glycine Substances 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
-1 alkyl p-hydroxybenzoates Chemical class 0.000 description 4
239000003125 aqueous solvent Substances 0.000 description 4
239000006172 buffering agent Substances 0.000 description 4
229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 4
150000004683 dihydrates Chemical class 0.000 description 4
239000008187 granular material Substances 0.000 description 4
239000002674 ointment Substances 0.000 description 4
229940083542 sodium Drugs 0.000 description 4
229960002668 sodium chloride Drugs 0.000 description 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241000972773 Aulopiformes Species 0.000 description 3
KSIYPKPZIBBUFR-LJNLPFSOSA-N CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O Chemical compound CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O KSIYPKPZIBBUFR-LJNLPFSOSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101000741445 Homo sapiens Calcitonin Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
101000910302 Sus scrofa Calcitonin Proteins 0.000 description 3
239000004479 aerosol dispenser Substances 0.000 description 3
239000006196 drop Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
235000019197 fats Nutrition 0.000 description 3
229940116364 hard fat Drugs 0.000 description 3
229940045644 human calcitonin Drugs 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
239000003921 oil Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000003285 pharmacodynamic effect Effects 0.000 description 3
229940057847 polyethylene glycol 600 Drugs 0.000 description 3
229940093429 polyethylene glycol 6000 Drugs 0.000 description 3
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
235000019515 salmon Nutrition 0.000 description 3
108010068072 salmon calcitonin Proteins 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000002904 solvent Substances 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 2
101100279860 Caenorhabditis elegans epg-2 gene Proteins 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
229920003137 Eudragit® S polymer Polymers 0.000 description 2
101000741447 Gallus gallus Calcitonin Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000010191 Osteitis Deformans Diseases 0.000 description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229940124532 absorption promoter Drugs 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000001361 adipic acid Substances 0.000 description 2
235000011037 adipic acid Nutrition 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000007963 capsule composition Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000003240 coconut oil Substances 0.000 description 2
235000019864 coconut oil Nutrition 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
229960004949 glycyrrhizic acid Drugs 0.000 description 2
235000019410 glycyrrhizin Nutrition 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000007794 irritation Effects 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
210000002850 nasal mucosa Anatomy 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
229940068918 polyethylene glycol 400 Drugs 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
239000003380 propellant Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
229940087562 sodium acetate trihydrate Drugs 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000006190 sub-lingual tablet Substances 0.000 description 2
239000002511 suppository base Substances 0.000 description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
IVQOFBKHQCTVQV-UHFFFAOYSA-N 2-hydroxy-2,2-diphenylacetic acid 2-(diethylamino)ethyl ester Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCCN(CC)CC)C1=CC=CC=C1 IVQOFBKHQCTVQV-UHFFFAOYSA-N 0.000 description 1
SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
101100533230 Caenorhabditis elegans ser-2 gene Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241001125671 Eretmochelys imbricata Species 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
241000447437 Gerreidae Species 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
101000910296 Ovis aries Calcitonin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
208000027067 Paget disease of bone Diseases 0.000 description 1
229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101000910301 Rattus norvegicus Calcitonin Proteins 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001323 aldoses Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
229940043377 alpha-cyclodextrin Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
208000016738 bone Paget disease Diseases 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
150000002302 glucosamines Chemical class 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000000205 hypercalcaemic effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
239000003346 palm kernel oil Substances 0.000 description 1
235000019865 palm kernel oil Nutrition 0.000 description 1
229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229940113115 polyethylene glycol 200 Drugs 0.000 description 1
229940068886 polyethylene glycol 300 Drugs 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
229940043131 pyroglutamate Drugs 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
235000011091 sodium acetates Nutrition 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
229940083608 sodium hydroxide Drugs 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
WRZYGPIFICWRCG-OOFFSTKBSA-M sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trih Chemical compound [Na+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O WRZYGPIFICWRCG-OOFFSTKBSA-M 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229940098466 sublingual tablet Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
229950004616 tribromoethanol Drugs 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

CA002120755A 1991-10-11 1992-10-08 Pharmaceutical compositions comprising a calcitonin, a glycyrrhizinate as absorption enhancer and benzyl Abandoned CA2120755A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ITMI912703A IT1251685B (it)	1991-10-11	1991-10-11	Composizioni farmaceutiche contenenti una calcitonina
ITMI91A002703		1991-10-11

Publications (1)

Publication Number	Publication Date
CA2120755A1 true CA2120755A1 (en)	1993-04-15

Family

ID=11360856

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002120755A Abandoned CA2120755A1 (en)	1991-10-11	1992-10-08	Pharmaceutical compositions comprising a calcitonin, a glycyrrhizinate as absorption enhancer and benzyl

Country Status (9)

Country	Link
EP (1)	EP0607229A1 (it)
JP (1)	JPH07500099A (it)
AU (1)	AU2683492A (it)
BR (1)	BR9206707A (it)
CA (1)	CA2120755A1 (it)
IT (1)	IT1251685B (it)
MX (1)	MX9205852A (it)
PT (1)	PT100946A (it)
WO (1)	WO1993006854A1 (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2285921A (en) *	1994-01-31	1995-08-02	Leilani Lea	Sublingual administration of medicaments
DE726075T1 (de) *	1995-02-08	1996-12-12	Therapicon Srl	Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
AU1808897A (en) *	1995-12-13	1997-07-03	Dullatur Limited	A calcitonin preparation
IT1294191B1 (it) *	1997-09-05	1999-03-22	Alfa Wassermann Spa	Composizioni farmaceutiche contenenti calcitonina in un dosatore spray per somministrazione intranasale.
GB2368792A (en)	2000-10-06	2002-05-15	Roger Randal Charles New	Absorption enhancers
ITRM20010048A1 (it) *	2001-01-30	2002-07-30	Gregorio Mauro De	Metodo per preparare soluzioni acquose fisiologicamente accettabili esoluzioni cosi' ottenute.
GB0308734D0 (en)	2003-04-15	2003-05-21	Axcess Ltd	Uptake of macromolecules
GB0308732D0 (en) *	2003-04-15	2003-05-21	Axcess Ltd	Absorption enhancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60188315A (ja) *	1984-03-07	1985-09-25	Yamanouchi Pharmaceut Co Ltd	グリチルレチン酸配合鎮痒プラスター
JPS61267528A (ja) *	1984-11-26	1986-11-27	Yamanouchi Pharmaceut Co Ltd	吸収促進剤を含有するカルシトニン経鼻剤
GB2212062B (en) *	1987-11-13	1991-07-17	Isf Spa	Pharmaceutical compositions containing a calcitonin and a glycyrrhizinate ab- sorption enhancer
JPH078806B2 (ja) *	1990-08-16	1995-02-01	旭化成工業株式会社	カルシトニン類含有経鼻投与用乳剤

1991
- 1991-10-11 IT ITMI912703A patent/IT1251685B/it active IP Right Grant
1992
- 1992-10-08 AU AU26834/92A patent/AU2683492A/en not_active Abandoned
- 1992-10-08 BR BR9206707A patent/BR9206707A/pt not_active Application Discontinuation
- 1992-10-08 CA CA002120755A patent/CA2120755A1/en not_active Abandoned
- 1992-10-08 EP EP92920956A patent/EP0607229A1/en not_active Withdrawn
- 1992-10-08 JP JP5506629A patent/JPH07500099A/ja active Pending
- 1992-10-08 WO PCT/EP1992/002321 patent/WO1993006854A1/en not_active Ceased
- 1992-10-09 MX MX9205852A patent/MX9205852A/es unknown
- 1992-10-09 PT PT100946A patent/PT100946A/pt not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO1993006854A1 (en)	1993-04-15
EP0607229A1 (en)	1994-07-27
JPH07500099A (ja)	1995-01-05
IT1251685B (it)	1995-05-19
AU2683492A (en)	1993-05-03
BR9206707A (pt)	1995-10-31
ITMI912703A1 (it)	1993-04-11
MX9205852A (es)	1993-06-01
ITMI912703A0 (it)	1991-10-11
PT100946A (pt)	1993-10-29

Legal Events

Date	Code	Title	Description
1997-10-08	FZDE	Discontinued

Publication	Publication Date	Title
US5719122A (en)	1998-02-17	Pharmaceutical compositions containing a calcitonin
EP0397447B1 (en)	1994-01-19	Pharmaceutical compositions
EP0327756B1 (en)	1994-01-26	Pharmaceutical compositions comprising a calcitonin and a glycyrrhizinate as absorption enhancer
AU2005247439B2 (en)	2010-02-11	A biomolecule-containing formulation of increased stability
US4153689A (en)	1979-05-08	Stable insulin preparation for nasal administration
KR0138658B1 (ko)	1998-05-15	생물학적활성폴리펩티드를포함하는질내투여용약제학적조성물
PL194268B1 (pl)	2007-05-31	Wodny farmaceutyczny roztwór zawierający hormon przytarczyc oraz sposób jego wytwarzania
EP0566135A1 (en)	1993-10-20	Transmucosal composition comprising a peptide and a cytidine derivative
DE4131232A1 (de)	1992-03-26	Pharmazeutische nasalzusammensetzung
JPH05508616A (ja)	1993-12-02	治療用エアロゾル剤
CZ260195A3 (en)	1996-01-17	Pharmaceutical preparation containing lipophilic therapeutical matters
GB9523442D0 (en)	1996-01-17	Calcitonin salmon analogues,their preparation,medicinal use and use as analytical agents
KR950004697B1 (ko)	1995-05-04	안정화된 칼시토닌 약학 조성물
CA2164193C (en)	2007-09-18	Intravaginal preparation containing physiologically active peptide
WO1993006854A1 (en)	1993-04-15	Pharmaceutical compositions comprising a calcitonin, a glycyrrhizinate as absorption enhancer and benzyl
CA1329764C (en)	1994-05-24	Pharmaceutical compositions
CA2754593A1 (en)	2010-10-07	Peptide pharmaceuticals for nasal delivery
CN119968205A (zh)	2025-05-09	口服多肽组合物及其用途
JPH0669956B2 (ja)	1994-09-07	ポリペプタイド類の吸着防止剤
JPH0725662B2 (ja)	1995-03-22	使用時調製型上皮細胞成長因子含有水性薬剤の安定化方法